Xu Jingren

Xu Jingren
Born	徐镜人 (Xu Jingren) 1944 (age 72–73) Jiangsu, China
Residence	Taizhou, Jiangsu
Nationality	People's Republic of China
Education	B.A.
Occupation	Pharmaceutical executive, philanthropist
Net worth	US$ 2.4 billion (June 2017)
Children	2
Website	http://web.archive.org/web/20151008020758/http://www.yangzijiang.com:80/

Xu Jingren (Chinese: 徐镜人) born 1944, is the chairman and president of Yangtze River Pharmaceutical Group,National People's Congress delegate and honorary vice-minister in China's Ministry of Health, and co-president of Beijing SL Pharmaceutical, which he founded with nephew Xu Mingbo. Xu has been an outspoken research leader in China, where he has frequently called for labor reform and business regulation. As of 2015, his estimated net worth is USD$1.9 billion, one of four family members to be listed among the world's wealthiest. Co-investor Xu Mingbo was also recognized (USD$1.1 billion).

The Xu family are prominent investors in diversified industries. In addition to controlling stakes in Yangtze River Pharmaceutical Group and Beijing SL Pharmaceuticals, Jingren chairs YRPG's 22 subsidiaries across Southeast Asia. His son Xu Haoyu is the largest private shareholder of China Eastern Airlines, based in Shanghai, China.

Xu's daughter, a pharmaceutical investor in the United States, negotiated the sale of majority ownership in research subsidiary ShangPharma, and holds board partnerships in China Telecom as well as Fosun Pharmaceutical. Her son Aaron Shang is currently a student in the United States. He retains a minority stake in re-branded ShangPharma/ChemPartner, and in 2015 introduced the group's new research centers in Shanghai and San Francisco alongside CEO Michael Hui. Shang also acquired an undisclosed percentage of French resort operator Club Med after funding a portion of the reportedly 80% premium that incoming owner Fosun International paid following a protracted bidding war.

...
Wikipedia